MKM Partners commented on Amarin Corporation (NASDAQ: AMRN) Tuesday following another NCE decision delay on Vascepa.

Analyst Jon LeCroy ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE